Molecule
Ibritumomab tiuxetan is a prescription medicine indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), among other approved uses. It is available as kits. MedsAcross supplies Ibritumomab tiuxetan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Zevalin is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of adult patients with: relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy.
Source: US FDA prescribing information
Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35). The apparent affinity (K D ) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to 18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkin’s lymphomas (NHL). The CD20 antigen is not shed from the cell surface and does not internalize upon antibody binding. The chelate tiuxetan, which tightly binds Y-90, is covalently linked to ibritumomab. The beta emission from Y-90 induces cellular damage by the formation of free radicals in the target and neighboring cells.
Source: US FDA prescribing information
Day 1: Administer rituximab 250 mg/m 2 intravenous infusion. Day 7, 8, or 9: Administer rituximab 250 mg/m 2 intravenous infusion. If platelets at least 150,000/mm 3: Within 4 hours after rituximab infusion, administer 0.4 mCi/kg (14.8 MBq per kg) Y-90 Zevalin intravenous infusion. If platelets 100,000 to 149,000/mm 3 in relapsed or refractory patients: Within 4 hours after rituximab infusion, administer 0.3 mCi/kg (11.1 MBq per kg) Y-90 Zevalin intravenous infusion.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Boxed warning: Serious Infusion Reactions: Deaths have occurred within 24 hours of rituximab infusion, an essential component of the Zevalin therapeutic regimen. These fatalities were associated with hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock. Most (80%) fatalities occurred with the first rituximab infusion. Serious Infusion Reactions: Immediately discontinue rituximab and Y-90 Zevalin. Prolonged and Severe Cytopenias: Do not administer Zevalin to patients with ≥ 25% lymphoma marrow involvement or impaired bone marrow reserve. Severe Cutaneous and Mucocutaneous Reactions: Discontinue rituximab and Zevalin infusions if patients develop severe cutaneous or mucocutaneous reactions.
Source: US FDA prescribing information
The following serious adverse reactions are discussed in greater detail in other sections of the label: Serious Infusion Reactions. Prolonged and Severe Cytopenias. Severe Cutaneous and Mucocutaneous Reactions. Leukemia and Myelodysplastic Syndrome. Common adverse reactions ( > 10%) in clinical trials were: cytopenias, fatigue, nasopharyngitis, nausea, abdominal pain, asthenia, cough, diarrhea, and pyrexia.
Source: US FDA prescribing information
Patients receiving medications that interfere with platelet function or coagulation should have more frequent laboratory monitoring for thrombocytopenia. No formal drug interaction studies have been performed with Zevalin. Monitor patients receiving medications that interfere with platelet function or coagulation more frequently for thrombocytopenia.
Source: US FDA prescribing information
Storage Store the kit at 2-8°C (36-46°F). Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Ibritumomab tiuxetan, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Zevalin kit Cold chain | Acrotech Biopharma | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 19 February 2002 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Ibritumomab tiuxetan and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Ibritumomab tiuxetan, including Zevalin.
Yes. The US FDA first approved Ibritumomab tiuxetan on 19 February 2002, according to Drugs@FDA.
At least one listed presentation of Ibritumomab tiuxetan must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.